Inhibrx Insider ownership
What is the Insider ownership of Inhibrx?
The Insider ownership of Inhibrx, Inc. is 31.49%
What is the definition of Insider ownership?
Insider Ownership is calculated as the total number of shares owned by insiders (shareholders who own more than 5% of the corporation or an officer or director of the company) divided by the total Shares Outstanding.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Insider ownership of companies in the Health Care sector on NASDAQ compared to Inhibrx
What does Inhibrx do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Companies with insider ownership similar to Inhibrx
- Damstra Ltd has Insider ownership of 31.45%
- Kalina Power has Insider ownership of 31.45%
- Chamberlin plc has Insider ownership of 31.45%
- Touax SCA has Insider ownership of 31.45%
- eGain Corp has Insider ownership of 31.46%
- BiVictriX Therapeutics plc has Insider ownership of 31.48%
- Inhibrx has Insider ownership of 31.49%
- Super Retail has Insider ownership of 31.49%
- RE Royalties has Insider ownership of 31.50%
- Andritz AG has Insider ownership of 31.50%
- OMV AG has Insider ownership of 31.50%
- Recticel SA/NV has Insider ownership of 31.51%
- Delivery Hero SE has Insider ownership of 31.51%